AbbVie

ABBV

Market cap $369B

The stocks listed here offer investors high dividend yields, well above the S&P 500 average. They also outperformed the index back in 2022, when the market crashed.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

The latest trading day saw AbbVie (ABBV) settling at $210.26, representing a +1.84% change from its previous close.

AbbVie's weight-loss candidate recently posted strong results in a phase 1 study. However, this is an increasingly competitive area in which the company will struggle to impose itself.

As the Q1 2026 earnings season plays out, the focus is shifting from short-term performance to long-term income potential, with investors zeroing in on companies that continue to reward shareholders consistently through dividends.

The entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle ® breast implants. As a champion of authenticity, Lichy hopes her transparency will help normalize the conversation around breast surgery.

Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and offer dividend yields even higher than oil and gas stocks, as well as the "Magnificent 7." By opening this article, you will find out my "top 4 Big Pharma players."

ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treatments.

All three of these titles are well known in their respective sectors. They also happen to be Dividend Kings.

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company.